-
Something wrong with this record ?
Drug-target interaction prediction: A Bayesian ranking approach
L. Peska, K. Buza, J. Koller,
Language English Country Ireland
Document type Journal Article
- MeSH
- Algorithms MeSH
- Bayes Theorem * MeSH
- Datasets as Topic MeSH
- Pharmacology * MeSH
- Humans MeSH
- Drug Repositioning MeSH
- Machine Learning MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND OBJECTIVE: In silico prediction of drug-target interactions (DTI) could provide valuable information and speed-up the process of drug repositioning - finding novel usage for existing drugs. In our work, we focus on machine learning algorithms supporting drug-centric repositioning approach, which aims to find novel usage for existing or abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects the needs of drug-centric repositioning research better than conventional drug-target prediction approaches. METHODS: We propose Bayesian Ranking Prediction of Drug-Target Interactions (BRDTI). The method is based on Bayesian Personalized Ranking matrix factorization (BPR) which has been shown to be an excellent approach for various preference learning tasks, however, it has not been used for DTI prediction previously. In order to successfully deal with DTI challenges, we extended BPR by proposing: (i) the incorporation of target bias, (ii) a technique to handle new drugs and (iii) content alignment to take structural similarities of drugs and targets into account. RESULTS: Evaluation on five benchmark datasets shows that BRDTI outperforms several state-of-the-art approaches in terms of per-drug nDCG and AUC. BRDTI results w.r.t. nDCG are 0.929, 0.953, 0.948, 0.897 and 0.690 for G-Protein Coupled Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR), Enzymes (E) and Kinase (K) datasets respectively. Additionally, BRDTI significantly outperformed other methods (BLM-NII, WNN-GIP, NetLapRLS and CMF) w.r.t. nDCG in 17 out of 20 cases. Furthermore, BRDTI was also shown to be able to predict novel drug-target interactions not contained in the original datasets. The average recall at top-10 predicted targets for each drug was 0.762, 0.560, 1.000 and 0.404 for GPCR, IC, NR, and E datasets respectively. CONCLUSIONS: Based on the evaluation, we can conclude that BRDTI is an appropriate choice for researchers looking for an in silico DTI prediction technique to be used in drug-centric repositioning scenarios. BRDTI Software and supplementary materials are available online at www.ksi.mff.cuni.cz/∼peska/BRDTI.
Brain Imaging Centre Hungarian Academy of Sciences Budapest Hungary
Faculty of Mathematics and Physics Charles University Prague Czech Republic
Institute of Genomic Medicine and Rare Disorders Semmelweis University Budapest Hungary
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033643
- 003
- CZ-PrNML
- 005
- 20181023111823.0
- 007
- ta
- 008
- 181008s2017 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cmpb.2017.09.003 $2 doi
- 035 __
- $a (PubMed)29054256
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Peska, Ladislav $u Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic; Brain Imaging Centre, Hungarian Academy of Sciences, Budapest, Hungary. Electronic address: peska@ksi.mff.cuni.cz.
- 245 10
- $a Drug-target interaction prediction: A Bayesian ranking approach / $c L. Peska, K. Buza, J. Koller,
- 520 9_
- $a BACKGROUND AND OBJECTIVE: In silico prediction of drug-target interactions (DTI) could provide valuable information and speed-up the process of drug repositioning - finding novel usage for existing drugs. In our work, we focus on machine learning algorithms supporting drug-centric repositioning approach, which aims to find novel usage for existing or abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects the needs of drug-centric repositioning research better than conventional drug-target prediction approaches. METHODS: We propose Bayesian Ranking Prediction of Drug-Target Interactions (BRDTI). The method is based on Bayesian Personalized Ranking matrix factorization (BPR) which has been shown to be an excellent approach for various preference learning tasks, however, it has not been used for DTI prediction previously. In order to successfully deal with DTI challenges, we extended BPR by proposing: (i) the incorporation of target bias, (ii) a technique to handle new drugs and (iii) content alignment to take structural similarities of drugs and targets into account. RESULTS: Evaluation on five benchmark datasets shows that BRDTI outperforms several state-of-the-art approaches in terms of per-drug nDCG and AUC. BRDTI results w.r.t. nDCG are 0.929, 0.953, 0.948, 0.897 and 0.690 for G-Protein Coupled Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR), Enzymes (E) and Kinase (K) datasets respectively. Additionally, BRDTI significantly outperformed other methods (BLM-NII, WNN-GIP, NetLapRLS and CMF) w.r.t. nDCG in 17 out of 20 cases. Furthermore, BRDTI was also shown to be able to predict novel drug-target interactions not contained in the original datasets. The average recall at top-10 predicted targets for each drug was 0.762, 0.560, 1.000 and 0.404 for GPCR, IC, NR, and E datasets respectively. CONCLUSIONS: Based on the evaluation, we can conclude that BRDTI is an appropriate choice for researchers looking for an in silico DTI prediction technique to be used in drug-centric repositioning scenarios. BRDTI Software and supplementary materials are available online at www.ksi.mff.cuni.cz/∼peska/BRDTI.
- 650 _2
- $a algoritmy $7 D000465
- 650 12
- $a Bayesova věta $7 D001499
- 650 _2
- $a datové soubory jako téma $7 D066264
- 650 _2
- $a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a strojové učení $7 D000069550
- 650 12
- $a farmakologie $7 D010600
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Buza, Krisztian $u Brain Imaging Centre, Hungarian Academy of Sciences, Budapest, Hungary; Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
- 700 1_
- $a Koller, Júlia $u Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary.
- 773 0_
- $w MED00001214 $t Computer methods and programs in biomedicine $x 1872-7565 $g Roč. 152, č. - (2017), s. 15-21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29054256 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181023112330 $b ABA008
- 999 __
- $a ok $b bmc $g 1340957 $s 1030637
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 152 $c - $d 15-21 $e 20170908 $i 1872-7565 $m Computer methods and programs in biomedicine $n Comput Methods Programs Biomed $x MED00001214
- LZP __
- $a Pubmed-20181008